Month: March 2019


Takeda Signs a Multi-Target Agreement with StrideBio to Develop Gene

 Shots: StrideBio to receive $30M upfront & near term pre-clinical milestones, $680M as development and commercial milestones & royalties on global sales of products. Takeda to get rights for clinical development and commercialization of selected products developed StrideBio will take care of preclinical development & manufacturing of in vivo AAV based gene-therapies for Takeda’s three […]Read More


Mitsubishi Tanabe Pharma (MTPA) Collaborates with Massachusetts General Hospital (MGH)

Shots: Mitsubishi Tanabe Pharma (MTPA) enters into a collaboration with Massachusetts General Hospital (MGH) Neurological Clinical Research Institute (NCRI) to conduct ALS biomarker study for identification of biomarkers in patients with amyotrophic lateral sclerosis (ALS) The ALS biomarker study will evaluate 4 biomarkers enrolling 200 patients receiving Radicava (edaravone) for 24wks. across 40 sites and […]Read More


AstraZeneca Signs a Worldwide Development and Commercialization Agreement with Daiichi

Shots: Daiichi Sankyo to receive $1.35B upfront, $5.55B as regulatory & commercial milestones making the total deal value $6.9B. AstraZeneca to get WW co-development and co-commercialization rights for Daiichi’s trastuzumab deruxtecan (Ex- Japan) with equal cost & profit sharing The focus of the collaboration is to develop trastuzumab deruxtecan for HER2+ breast and gastric cancer […]Read More


Bayer Signs a Non-Exclusive Licensing Agreement with ProteoNic Biotechnology for

Shots: Bayer to get non-exclusive WW license rights to develop and commercialize its own products by using ProteoNic’s 2G UNic Technology  The focus of the collaboration is to produce and enhance Bayer recombinant proteins portfolio utilizing ProteoNic’s 2G UNic Technology ProteoNic’s 2G UNic Technology is a protein expression technology designed to improve cell line production […]Read More


Johnson & Johnson (J&J) Vision Launches Acuvue Oasys with Transitions

Shots: J&J Vision’s Acuvue Oasys with transitions light intelligent technology is evaluated in 1000 patients results demonstrated 67% performs better in doing physical activities, 55% feel stress exposing bright & harsh light, 56% adjust light condition quickly On Apr 11, 2018 J&J Vision collaborated with Transitions Optical Limited to develop Acuvue Oasys, a lens providing […]Read More


Apple Launches its Watch Series 4 Enabled with ECG App

Shots: The ECG app on Apple Watch Series 4 is evaluated in 600 patients resulted in 98.3% sensitivity in classifying AFib, 99.6% specificity in classifying sinus rhythm, 87.8% of recordings classified by the ECG app The irregular rhythm notification function was assessed in the Apple Heart study enrolled with 400,000 candidates and demonstrated 0.5% irregular […]Read More


Ono Pharmaceutical Signs a Multi-Year Collaboration with LifeArc and Cancer

Shots: Cancer Research and LifeArc to receive upfront, milestones and royalties on sales of products. Ono to get an option to license the developed product with exclusive WW commercialization rights and will take care of its clinical development for identifying new therapeutic targets & target validation LifeArc will utilize its antibody screening and development expertise […]Read More


Chugai’s Risdiplam Receives MHLW’s Orphan Drug Designation for Spinal Muscular

Shots: The MHLW’s ODD follows P-II/III (FIREFISH, SUNFISH) study assessing Risdiplam in patients with  spinal muscular atrophy (SMA) in Japan  Chugai & Roche collaborated for the clinical development Risdiplam, first oral systemic therapy for SMA Risdiplam (RG7916) is survival motor neuron-2 (SMN2) splicing modifier targeted to increase SMN protein levels in CNS and has received […]Read More